Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518451 | 0.82 | CES2 (0.41) | AKR1C3AKR1C2LMNAKMT2AMEN1 | |
| SCHEMBL30846954 | 0.82 | CES2 (0.41) | AKR1C3AKR1C2LMNAKMT2AMEN1 | |
| SCHEMBL84459 | 0.82 | LMNA (0.58) | AKR1C3AKR1C2LMNAKMT2AMEN1 | |
| SCHEMBL8256534 | 0.82 | AKR1C3 (0.47) | AKR1C3AKR1C2LMNAKMT2AMEN1 | |
| SCHEMBL25560975 | 0.81 | AKR1C3 (0.41) | AKR1C3AKR1C2LMNAKMT2AMEN1 | |
| SCHEMBL24569197 | 0.80 | AKR1C3 (0.46) | AKR1C3AKR1C2LMNAKMT2AMEN1 | |
| SCHEMBL4076370 | 0.79 | LMNA (0.43) | LMNAALDH1A1TRPA1PTGS1CACNA1C | |
| SCHEMBL21831869 | 0.78 | KDM1A (0.36) | AKR1C3AKR1C2LMNAKMT2AMEN1 | |
| SCHEMBL20488728 | 0.78 | AKR1C3 (0.49) | AKR1C3AKR1C2LMNAKMT2AMEN1 | |
| SCHEMBL22032268 | 0.78 | AKR1C3 (0.45) | AKR1C3AKR1C2LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011289-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2025-01-09 | — | — | US | disclosed |
| CN-118525007-A | 1H-benzo [ B ] azepin-2 (3H) -one compounds, compositions and methods for treating cancer | 成都安泰康赛生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023088420-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2023-05-25 | — | — | WO | disclosed |
| WO-2004110997-A1 | 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| US-4633026-A | DEHYDROHALOGENATION OF RING-HALOGENATED ALPHA- OR BETA-BROMOETHYL BENZENES WITH STRONG BASE, POLYOXYETHYLENE GLYCOL CATALYST, AMINE POLYMERIZATION INHIBITOR | ETHYL CORPORATION (US) | 1986-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011289-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | BRCA1, TP53, BCCIP | AKR1C3 3492/4885AKR1C2 2509/4885LMNA 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.